Tetraphase Pharmaceuticals (TTPH) PT Lowered to $6.00

Tetraphase Pharmaceuticals (NASDAQ:TTPH) had its target price lowered by investment analysts at Stifel Nicolaus from $13.00 to $6.00 in a research report issued to clients and investors on Wednesday, Marketbeat reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price points to a potential upside of 179.07% from the stock’s current price.

A number of other equities research analysts also recently commented on TTPH. BMO Capital Markets downgraded Tetraphase Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price for the company. in a report on Wednesday. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $8.00 target price on shares of Tetraphase Pharmaceuticals in a report on Wednesday. HC Wainwright decreased their target price on Tetraphase Pharmaceuticals from $17.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday. BidaskClub downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Finally, B. Riley began coverage on Tetraphase Pharmaceuticals in a report on Monday. They set a “buy” rating and a $11.00 target price for the company. Two analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. Tetraphase Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $10.39.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded down $3.28 during trading on Wednesday, hitting $2.15. The company had a trading volume of 16,861,522 shares, compared to its average volume of 461,216. Tetraphase Pharmaceuticals has a 12-month low of $2.10 and a 12-month high of $9.93. The firm has a market capitalization of $110.93, a P/E ratio of -0.75 and a beta of 2.28.

In related news, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $6.22, for a total transaction of $54,425.00. Following the completion of the transaction, the insider now directly owns 8,750 shares in the company, valued at $54,425. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director L Patrick Gage purchased 3,880 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Wednesday, November 29th. The shares were bought at an average price of $6.45 per share, with a total value of $25,026.00. Following the completion of the transaction, the director now owns 38,880 shares of the company’s stock, valued at approximately $250,776. The disclosure for this purchase can be found here. 5.50% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new position in Tetraphase Pharmaceuticals during the third quarter valued at approximately $107,000. Brighton Jones LLC purchased a new position in Tetraphase Pharmaceuticals during the third quarter valued at approximately $108,000. Voya Investment Management LLC raised its position in Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 3,104 shares in the last quarter. Virtu KCG Holdings LLC purchased a new position in Tetraphase Pharmaceuticals during the second quarter valued at approximately $147,000. Finally, Ameriprise Financial Inc. purchased a new position in Tetraphase Pharmaceuticals during the second quarter valued at approximately $162,000. Institutional investors own 58.28% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Tetraphase Pharmaceuticals (TTPH) PT Lowered to $6.00” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/14/tetraphase-pharmaceuticals-ttph-pt-lowered-to-6-00.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply